- Home
- ENTA
as of 12-31-2025 3:53pm EST
$15.87
$0.04
-0.22%
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 486.3M | IPO Year: | 2013 |
| Target Price: | $20.40 | AVG Volume (30 days): | 370.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.09 - $17.15 | Next Earning Date: | 02-09-2026 |
| Revenue: | $65,324,000 | Revenue Growth: | -3.42% |
| Revenue Growth (this year): | 0.99% | Revenue Growth (next year): | 0.19% |
AI-Powered ENTA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 80.26%
80.26%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Enanta Pharmaceuticals Inc. (ENTA)
Capps Kathleen S.
Sell
See Remarks
ENTA Dec 2, 2025
Avg Cost/Share
$13.96
Shares
207
Total Value
$2,889.72
Owned After
8,700
SEC Form 4
Trout Harry R. III
Sell
See Remarks
ENTA Dec 2, 2025
Avg Cost/Share
$13.96
Shares
380
Total Value
$5,304.80
Owned After
16,890
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Capps Kathleen S. | ENTA | See Remarks | Dec 2, 2025 | Sell | $13.96 | 207 | $2,889.72 | 8,700 | |
| Trout Harry R. III | ENTA | See Remarks | Dec 2, 2025 | Sell | $13.96 | 380 | $5,304.80 | 16,890 |
Latest Enanta Pharmaceuticals Inc. News
ENTA Breaking Stock News: Dive into ENTA Ticker-Specific Updates for Smart Investing
Compare ENTA vs Leading Stocks
See how ENTA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ENTA Enanta Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.